ACTIVITY TITLE
Virtual Symposium: Challenges and Advances in the Diagnosis and Management of Heart Failure with Preserved Ejection
Fraction
ACTIVITY FORMAT
Virtual Symposium
PROGRAM DESCRIPTION
Prognosis and treatment of heart failure patients with preserved ejection fraction (HFpEF) is complicated by
diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction
(HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as
obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased
risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning.
The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease,
and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in
managing HFpEF. Advancements in disease pathophysiology, diagnostic tools, current and emerging treatment options
may give clinicians additional tools to improve the outcomes of the disease; including morbidity, mortality, and
quality of life.
To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to
diagnose and manage HFpEF, including patients with comorbidities. This symposium will also provide an overview on
current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.
ESTIMATED TIME TO COMPLETE: 75 minutes
RELEASE DATE: December 27, 2019
EXPIRATION DATE: December 27, 2020
EDUCATIONAL GRANT SUPPORT
This educational activity is multi-supported by educational grants from Abbott and Novartis Pharmaceuticals
Corporation.
INTENDED AUDIENCE
This activity is designed for US-based endocrinologists, cardiologists, lipidologists, diabetologists,
gastroenterologists, hepatologists, PAs, registered nurses, and NPs
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Identify HFpEF based on current and emerging diagnostic approaches
- Develop individualized treatment regimens for HFpEF patients with comorbidities based on current guidelines
and evidence
- Interpret the efficacy and safety of emerging treatment options and therapeutic strategies in HFpEF based on
the latest clinical trial evidence
- List approaches and resources aimed to improve hospital readmission rates for patients with HFpEF
FACULTY
Mariell Jessup, MD (Chair)
- Chief Science and Medical Officer
- American Heart Association
- Dallas, TX
Javed Butler, MD, MPH, MBA
- Professor and Chairman, Department of Medicine
- University of Mississippi
- Jackson, MS
Alanna A. Morris, MD
- Assistant Professor of Medicine, Division of Cardiology
- Emory University Clinical Cardiovascular Research Institute
- Atlanta, GA
Ileana L. Piña, MD, MPH, FAHA, FACC
- Clinical Prof of Medicine, Central Michigan University
- Director CVD Research and Academic Affairs
- Regional and National Director of Heart Failure
- Detroit Medical Center
- Detroit, MI
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute
for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American
Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category
1
Credits™ Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Designated
for 0.1 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
PHARMACIST ACCREDITATION STATEMENT
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125
CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-20-1031-H01-P.
Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP
CPE Monitor Service within 4-6 weeks.
DIETICIAN ACCREDITATION STATEMENT
Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited
Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5
Continuing Professional Education units (CPEUs) for completion of this activity.
This is a Level II activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in
a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they
may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according
to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that
promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial
interest.
Faculty
Dr. Butler discloses the following:
- Consulting Fees: Novartis, Janssen, AZ, Merck, BI, NN, Sanofi
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Novartis, Janssen,
Novo Nordisk
Dr. Jessup has nothing to disclose.
Dr. Morris has nothing to disclose.
Dr. Piña discloses the following:
- Consulting Fees: Advisory Board – Relypsa, FDA CDRH Reviewer
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not
indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled
indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily
represent the views of the planners. Please refer to the official prescribing information for each product for
discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and
their own professional development. The information presented in this activity is not meant to serve as a guideline
for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and
possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and
comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 27,
2019 through December 27, 2020, participants must read the learning objectives and faculty disclosures and study
the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-survey and evaluation.
Upon completing, your certificate will be made available immediately.
Media: Internet
For questions about the accreditation of this activity, please visit
www.pimed.com.
HARDWARE AND SOFTWARE REQUIREMENTS:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not
have these browsers, you can download Chrome here,
Firefox here and
Internet Explorer
here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB
RAM.
